“Idea to software, fast.” We’re happy to announce our $20M investment in Replit, which underscores our excitement about their bold vision to empower the next billion software creators. One… Read More »Why We Invested in Replit
Previously we shared a high-level overview of the opportunities in fintech, highlighting financial wellness as an area we are especially interested in. The possibility of unlocking financial literacy and… Read More »Cents and sensibility: the role of technology in driving financial wellness
Earlier this summer, I had the honor of being asked to lead OMERS Ventures (OV). Every investment organization within OMERS bears a tremendous responsibility for investing on behalf of… Read More »OV 3.0. The constant state of change
Continuing our series on Vertical Software (VSaaS), we’re spotlighting the latest sector we’ve been focused on: Autotech. We’ve highlighted before that we believe successful VSaaS companies emerge from fragmented… Read More »Emerging trends in Autotech
Despite pervasive fear, uncertainty and doubt, and rumors of fintech’s demise, we believe that the fintech venture opportunity has never been stronger. It’s a space we know well and… Read More »Unlocking the future of finance: why we are all-in on fintech.
29 September 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Interim results for the six months ended 30 June 2023 Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing… Read More »Interim results for the six months ended 30 June 2023
Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developing a pipeline of products aimed… Read More »Biodexa Regain Compliance with NASDAQ Minimum Bid Price Requirement
6 July 2023 Biodexa Pharmaceuticals PLC(“Biodexa” or the “Company”) Results of Appeal of Delisting Determination Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical-stage biopharmaceutical company developing a pipeline of products aimed… Read More »Results of Appeal of Delisting Determination
Bernard Ross, CEO of Sky Medical Technology, explores the role medtech plays in alleviating challenges in wound care to enhance healthcare delivery and ultimately, drive a healthier and more productive population. … Read More »Enhancing standard of wound care with innovative medical technology
A study that aims to deliver a step change in the care of chronic wounds and reduce healthcare costs for wound management has begun patient trials in people with diabetes-related… Read More »Trials begin for wound sensors that may reduce diabetes related amputation